Article
EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile.
Cancer biology & therapy - 1 Jan 2016
Zhang Jiayin, Lu Biao, Liu Dong, Shen Ru, Yan Yinfa, Yang Liuqing, Zhang Minsheng, Zhang Lei, Cao Guoqing, Cao Hu, Fu Beibei, Gong Aishen, Sun Qiming, Wan Hong, Zhang Lianshan, Tao Weikang, Cao Jingsong
Abstract excerpt
The oncogenic mutation of BRAF(V600E) has been found in approximately 8% of all human cancers, including more than 60% of melanoma and 10% of colorectal cancers. The clinical proof of concept in treating BRAF(V600E)-driving melanoma patients with the BRAF inhibitors has been well established. We have sought to identify and develop novel BRAF(V600E) inhibitors with more favorable profiles. Our chemistry effort has...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.